Ortho-Phthalates Request for Information Comment Review
Closed Special Notice Posted
- Solicitation number
- 75F40123R00126
- Agency
- Office of Operations Food and Drug Administration, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- Place of performance
- Silver Spring, Maryland 20993, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The US Food and Drug Administration (FDA) intends to award a sole source contract to Goldbelt for assistance in reviewing comments and information and categorizing them to aid in the FDA's review process. The contract will be executed at the FDA's office in Silver Spring, MD. Interested parties have seven days from the publication of this notice to express their interest and capabilities, with responses to be emailed to Natapol Sirikhan by 08/07/23, 12:00 PM EST.
Products and Services to be provided:
- Review of received comments and information.
- Categorization of comments and information into pre-determined categories.
- Assistance in prioritizing FDA's review of the responsive information.
- Communication and coordination with the FDA.
- Response to any queries or clarifications needed by the FDA.
Notice text
2 versions
Update #2 · Latest ·
Notice of Intent Sole Source
This announcement is not a Request for Proposal.
The US Food and Drug Administration {FDA), Office of Finance Budget Acquisition and Planning, intends to award a sole source award to Goldbelt Professional Services, Inc., a previous contract holder, In accordance with the Partnership Agreement between SBA and the U.S. Department of Health and Human Services (HHS) effective October 23, 2012; to provide assistance with reviewing the received comments and information, and assigning them to pre-determined categories that will help prioritize FDA’s review of the responsive information; at
The US Food and Drug Administration 10903 New Hampshire Avenue Building 66 Silver Spring MD 20993.
The propose simplified acquisition is for services; the Government intends to solicit and negotiate to only one source. Interested parties may identify their interests and capabilities to respond to the requirement within seven (7) days after the publication of this notice. A determination by the Government not to compete this proposed simplified acquisition based upon responses to this notice, is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive requirement. No further solicitation is available.
FDA will consider all responses received prior to the closing date of this notice and will use responses in determining, whether it is necessary to use full and open competition for this requirement. Responses shall be emailed to Natapol Sirikhan, Natapol.Sirikhan@fda.hhs.gov, by 08/07/23, 12:00 PM EST.
Update #1 ·
Notice of Intent Sole Source
This announcement is not a Request for Proposal.
The US Food and Drug Administration {FDA), Office of Finance Budget Acquisition and Planning, intends to award a follow-on sole source award to Goldbelt, a previous incumbent contract holder; to provide assistance with reviewing the received comments and information, and assigning them to pre-determined categories that will help prioritize FDA’s review of the responsive information; at
The US Food and Drug Administration 10903 New Hampshire Avenue Building 66 Silver Spring MD 20993.
The propose simplified acquisition is for services; the Government intends to solicit and negotiate to only one source. Interested parties may identify their interests and capabilities to respond to the requirement within seven (7) days after the publication of this notice. A determination by the Government not to compete this proposed simplified acquisition based upon responses to this notice, is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive requirement. No further solicitation is available.
FDA will consider all responses received prior to the closing date of this notice and will use responses in determining, whether it is necessary to use full and open competition for this requirement. Responses shall be emailed to Natapol Sirikhan, Natapol.Sirikhan@fda.hhs.gov, by 08/07/23, 12:00 PM EST.
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity